Amgen Cuts Costs And Jobs, Despite Strong Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech is restructuring as some of its more successful products could face generic competition; cuts will be company-wide, but focused in the U.S.
You may also be interested in...
Emerging Markets Earnings Roundup: Amgen, Sanofi (Part 14)
Amgen is fairly quiet on international in the second quarter, but Sanofi says it is back on track in Brazil and emerging markets generally.
Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.